Women's health innovation is often framed as a balancing act between doing what is right and doing what is commercially viable — but this tension is misleading. As highlighted in a recent report by the Health Innovation Network, the opportunities in women's health extend far beyond addressing unmet clinical needs; they have the power to boost economic productivity, strengthen the workforce and close long-standing gaps in care. Yet the same report makes clear that meaningful progress depends on something deeper: innovations must be designed to work for all women, not only those who are already well‑served or digitally confident.
Too often, equity and profitability are positioned as opposing forces - the moral good versus the commercial gain, but that's a false trade-off. In reality, embedding equity into product design, data and delivery isn't a constraint on growth; it is a growth strategy. If women's health innovators want scale, adoption and trust, they must design for the full spectrum of women's lives, not just those who are digitally literate, well-resourced or privately insured. Equity doesn't dilute profit; it expands the market.
From ROI to population value
At Health Innovation Kent Surrey Sussex (Health Innovation KSS), we've been exploring how to redefine value in ways that combine both economic and population health logic. The question isn't just ‘What's the return on investment?' but ‘Who will benefit from it?' True value comes when innovation delivers both financial return and social impact, leading to better outcomes, greater inclusion and long-term sustainability.
Introducing the Triple Value Lens
The triple value lens recognises three interlocking dimensions of impact: public health value, social equity value and system & economic value, which together create what we call the Population Return on Innovation.
Public Health Value
This reflects measurable improvement in health outcomes, prevention and wellbeing. The strongest innovations improve quality of life, detect conditions earlier and prevent disease altogether. A digital menopause platform that helps women recognise symptoms, seek timely care and avoid complications creates tangible population health benefit. Crucially, population health value must be measured across the life course, from adolescence and reproductive years to menopause and beyond, recognising women's health needs evolve over time, therefore, innovations that adapt to these transitions will create enduring health and system benefits.
Social Equity Value
This is about who participates and who benefits. Innovations that are co-designed with people from diverse communities, use representative datasets and offer multilingual or low-data functionality build trust and legitimacy. Equity becomes a signal of quality, not a token of virtue. When innovations reflect the lived realities of women in different social, economic and cultural contexts, they gain authenticity and authenticity drives adoption. This dimension also includes psychological safety and digital confidence. For many women, especially those from marginalised groups, trust in technology depends on transparency, community endorsement and culturally relevant design. Social equity value, therefore, represents the relational dimension of innovation: trust, empowerment and agency.
System & Economic Value
Finally, innovations that improve efficiency, reduce avoidable demand, or support workforce participation contribute to both health system sustainability and economic productivity. A women's health platform that reduces unnecessary GP visits, prevents chronic complications, or helps women stay in work during menopause, delivers measurable returns to the system and the wider economy. This is where the moral and economic arguments meet: prevention and inclusion create resilience. The NHS Confederation estimates that for every £1 invested in women's health services, the return to the economy is £11. The same interventions that improve access for underserved women often generate the greatest savings for the system.
The Population Return on Innovation
At the centre of the Triple Value Lens lies the Population Return on Innovation, the point where better health, greater equity and stronger systems converge. When innovation delivers this triple value, it moves from being a market product to a public-good investment. It generates healthier women, stronger communities and more sustainable systems with outcomes that benefit everyone, not just investors. This concept reframes ROI for modern healthcare: not as a single metric of financial efficiency, but as a multidimensional measure of social, clinical and economic impact.
Achieving this requires deliberate action. For innovators, this means embedding equity into design from the outset and building products that work for women across all backgrounds and levels of digital confidence. For policymakers and commissioners, it means incentivising inclusive innovation, investing in prevention and prioritising solutions that deliver measurable public, social and economic value.
Health Innovation KSS is committed to advancing this mission - championing inclusive, evidence‑led innovation and supporting partners across the system to adopt approaches that generate population‑level benefit. The Triple Value Lens provides a practical roadmap for this work, balancing the moral imperative of fairness with the operational realities of investment, scale and long‑term sustainability. The organisations that embrace equity as a strategic advantage will not only accelerate adoption and build trust but will help shape a future where women's health innovation delivers meaningful value for all.
